H9N2 Avian Flu Cases Emerge in Italy and China

Overview

A cluster of human infections with influenza A(H9N2) — a strain of avian flu that circulates primarily in poultry — has drawn renewed attention from global health authorities in April 2026. Italy reported its first imported H9N2 case in a traveler returning from Senegal, while mainland China confirmed two additional human infections within days. Separately, the H5N1 strain continues to drive widespread outbreaks in commercial poultry flocks across the United States, and Taiwan documented an isolated H7 avian flu infection. Taken together, these developments underscore the persistent spillover risk that avian influenza subtypes pose at the human-animal interface — even as none of the current cases show evidence of sustained person-to-person transmission.

H9N2 is the most frequently detected avian influenza subtype in human infections globally, though it tends to cause milder illness than H5N1. Its significance lies less in immediate fatality risk and more in its role as a genetic donor: H9N2 has contributed internal gene segments to several other dangerous influenza strains, making it a virus of ongoing pandemic concern to virologists and public health planners alike.

Current Situation

Image: Pexels/Wikimedia Commons

Italy’s National IHR Focal Point formally notified the World Health Organization on 21 March 2026 of a laboratory-confirmed H9N2 infection in an adult male. Next-generation sequencing — a more thorough and precise method of viral identification than conventional testing — confirmed the subtype as influenza A(H9N2). The patient had recently returned from Senegal, making this the first imported H9N2 case recorded in Italy.

Crucially, epidemiological investigators found no identifiable exposure to poultry and no contact with any person displaying similar respiratory symptoms prior to the patient’s illness onset. That absence of a clear animal-source link complicates the investigation: it either points to an undetected exposure event, environmental contamination, or a gap in the patient’s recollection of activities while abroad.

In China, the Center for Disease Control and Prevention (China CDC) reported two additional H9N2 human cases as of 14 April 2026, according to CIDRAP’s coverage. No details were released regarding the patients’ symptom severity, exposure history, or recovery status — a transparency gap that public health advocates have repeatedly flagged in China’s avian flu reporting.

These cases are not epidemiologically linked to each other. However, their temporal clustering — multiple countries reporting H9N2 human infections within a few weeks — reflects the ongoing circulation of the virus in poultry populations across several regions simultaneously.

Affected Regions

Image: Pexels/Gustavo Fring

The geographic picture of current avian influenza activity spans several continents.

Italy is now the site of Europe’s most recently confirmed H9N2 human case, with the infection traced to travel in Senegal — a country in West Africa where poultry markets are widespread and avian influenza surveillance capacity is more limited than in higher-income nations. Italian health authorities have activated monitoring and containment protocols under IHR (2005) obligations, which require member states to notify WHO of any novel influenza A subtype infection in humans.

Mainland China remains the country with the highest historical burden of H9N2 human cases globally, and the two new April 2026 cases are consistent with the low but steady drumbeat of infections that Chinese authorities report each year. H9N2 is endemic in Chinese poultry, and most human cases there are associated with live bird market exposure, though reporting often lacks granular epidemiological detail.

In the United States, the dominant avian influenza concern remains H5N1. Indiana continues to be a focal point of poultry sector outbreaks, with the USDA’s Animal and Plant Health Inspection Service (APHIS) confirming outbreaks across 56 flocks in the past 30 days across the state’s hardest-hit counties, according to CIDRAP. While H5N1 has caused human infections in US farm workers in recent years, no new human cases are associated with this latest Indiana poultry wave.

Taiwan documented a single human H7 avian influenza infection in early April 2026. Taiwanese health officials stated that genomic analysis found no mutations that would meaningfully increase the virus’s ability to transmit between humans — a reassuring finding that lowers the immediate public health significance of that case.

Risk Assessment

Under the International Health Regulations (2005), any confirmed human infection with a novel influenza A subtype — one not normally circulating in the human population — constitutes a “potentially high public health impact” event requiring immediate WHO notification. H9N2 qualifies under this framework, which is why Italy’s report triggered formal international disclosure even for a single case.

WHO’s current global risk assessment for H9N2 remains low for the general public. The virus does not transmit efficiently between humans, and the cases reported to date show no evidence of secondary spread from person to person. However, the absence of a confirmed exposure source in the Italian case is a surveillance gap that warrants careful follow-up, particularly given the patient’s travel to a region with limited animal health monitoring infrastructure.

Several factors keep H9N2 on pandemic preparedness watch lists. First, the virus is widely distributed in poultry across Asia, the Middle East, and parts of Africa, meaning human exposure opportunities are frequent. Second, H9N2 has a documented history of donating internal gene segments to other influenza strains — it contributed to the emergence of the H7N9 strain that killed hundreds of people in China between 2013 and 2019. Third, population-level immunity to H9N2 is essentially nonexistent, meaning a strain that acquired efficient human transmissibility would encounter a fully susceptible global population.

Vulnerable populations for severe outcomes from any novel influenza subtype include the elderly, immunocompromised individuals, pregnant women, and people with chronic cardiopulmonary conditions. However, historical H9N2 human cases have often presented with mild to moderate respiratory illness, making severity profiling difficult when many mild cases go undetected.

Prevention & Response

Italian health authorities have implemented a suite of measures consistent with WHO guidance for novel influenza events: active contact tracing around the confirmed case, monitoring of close contacts for respiratory symptoms, and enhanced clinical surveillance at points of entry for travelers arriving from affected regions. The case has been reported through the established IHR mechanism, triggering information sharing with WHO and relevant member states.

WHO has not issued a travel or trade restriction related to the Italian H9N2 case, nor has it elevated its global pandemic preparedness phase. Routine guidance remains in effect: individuals working with poultry or in live animal markets in endemic regions should use appropriate personal protective equipment, practice good hand hygiene, and avoid direct contact with sick or dead birds.

There is currently no licensed H9N2-specific vaccine approved for human use, though candidate vaccines have been developed and stockpiled in some countries as a precautionary measure. Seasonal influenza vaccines offer no meaningful cross-protection against H9N2. Antiviral medications, particularly oseltamivir (Tamiflu) and baloxavir, are expected to retain activity against H9N2 based on current sensitivity data, and early treatment is recommended for confirmed or suspected cases in clinical settings.

For the ongoing US H5N1 poultry outbreak, APHIS continues to apply standard biosecurity and culling protocols at affected farms. Workers involved in depopulation activities at affected Indiana flocks are advised to follow CDC guidance on personal protective equipment and post-exposure antiviral prophylaxis.

The Taiwan H7 case triggered immediate genomic sequencing by local authorities — a response that reflects improved real-time surveillance infrastructure in the Asia-Pacific region. The finding that no concerning mutations were present has temporarily reduced concern about that particular detection.

Public health officials globally are monitoring whether the near-simultaneous emergence of H9N2 cases across multiple continents reflects increased viral activity in poultry reservoirs, improved detection capacity, or both. Enhanced genomic surveillance and rapid information sharing through platforms like WHO’s Global Influenza Surveillance and Response System (GISRS) remain the primary tools for tracking these developments in real time.

Sources

• World Health Organization — Disease Outbreak News: Avian Influenza A(H9N2), Italy (DON597, April 2026)
• CIDRAP (Center for Infectious Disease Research and Policy) — Two new H9N2 avian flu cases reported on mainland China (April 14, 2026)
• CIDRAP — Quick takes: Revised ACIP charter, human avian flu case in Italy, Salmonella outbreak, new polio cases (April 10, 2026)
• CIDRAP — Indiana tracks more avian flu in hard-hit counties (April 9, 2026)
• CIDRAP — Quick takes: Moringa Salmonella probe over, H7 flu case in Taiwan, H5N1 outbreaks in US poultry (April 2, 2026)